



Title: COVID-19 serological survey using micro blood sampling

549Authors: Melissa M. Matthews, Tae Gyun Kim, Satoshi Shibata, Noriko Shibata, Christian550Butcher, Jaekyung Hyun, Keon Young Kim, Theodore Robb, Siang Sheng Jheng, Masashi551Narita, Tomoari Mori, Mary Collins & Matthias Wolf





Supplementary Figure 1: Antibody Survey Sample Collection Kit and Plate Design. A. Each
blood sampling kit included BD Microtainer[®] contact-activated lancet (Becton Dickison, USA),
0.8 ml volume blood collection tube containing a coagulant and a separator (Greiner bio-one),
packaged alcohol wipes, adhesive bandage, and sticker with an identification barcode and QR
code. B. Front page of OIST Antibody Test website. C. Plate designs used in the ELISA. Plates
are modified versions of those described previously (1).



Supplementary Figure 2: Basic user flow followed by participants to view test results and

answer optional survey. The diagram was created with Microsoft Visio Professional.

SARS-CoV-2 MERS	RFVFLVLL-PLVSSQCVNLTTRTQLPPAYTNSTTRGVYYPDKVFRSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTRRFDNPVLPFNDGVYFA MIHSVFLLMFPLITPTESYVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKADGIIYPQGRTYSNITITYQGLF-PYQGHGMYVYSAGHATGTPQKLFVANYSQDVKQFANGFVN :*:::** * * * * * * :: : * * :*: * : *	
SARS-CoV-2 MERS	SYIKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYKKNNKSWMESEFRVYSSANNC IGAAANSTGTVIISPSTSATIRKIYPAFMLSSSVGNFSDGKMGRFFNHTIVILPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSDGNYNRNASLNSFKEYFNLRNC :* .:::*:::. : :::*::: * * * * * * *	166 237
SARS-CoV-2 MERS	TFEYVSQPFIMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNEN TFMTTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGG-NMFQFATLFVYDTIKYYSIIPHSIRSIQSDRKAWAAFYYYKLQFLTFLLDFSVD ** *.: .:* :* *:* ** * :** ** *: .** ** :** ** ********	282 330
SARS-CoV-2 MERS	GTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVI GYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAE-GVECDFSPLLSGT-PPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSY * * ***::: **: :*: :*: :*: :*: :*: :*:	402 448
SARS-CoV-2 MERS	RGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV PLSMKSDLSVSSAGPISQFNYKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRFLSDDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYYRKQLSPLEGGGWLVASGSTVAMTEQ ::::::::::::::::::::::::::::::::::::	
SARS-CoV-2 MERS	VVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDA-VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEV LQMGFGITVQYGTDTNSVCFKLEFANDTKIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFVYDAYQNLVGYYSDDGNYYCLRACVSVPVSVIYDKETKTHATLFGSVACEHI : :*: :** :** :*:* *:: *:: *:: *	620 682
SARS-CoV-2 MERS	PVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVN-NSYECDIPIGAGICASYQTQTNS-PASVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTK SSTMSQYSRSTRSMLKRRDSTYGPLQTFVGCVLGLVNSSLFVEDCKLPLGQSLCALPDTPSTLTPRSVRSVPGEMRLASIAFNHPIQ-VDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQK :: . : .: .: * .:: **:: * :: * :: * ::	730 801
SARS-CoV-2 MERS	TSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFN-FSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAR VTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTIADPGYMQGYDCMQQGPASAR .:***. *:* :*.:** :**.*** :**** ::::**** ::::**** ::::******::******	844 921
SARS-CoV-2 MERS	DLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLS DLICAQYVAGYKVLPPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFHKVQDAVNNNAQALSKLASELS ****** * * ******: :* * ***:** *** * .: **** :: *****:********	964 1041
SARS-CoV-2 MERS	SNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKA NTFGAISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQCTHIVSFVVNAPNGLYFMHVGYYSSNHIEVVSAYGLCDAANP *****:::**::**::**::**::*:::::::::::	1084 1161
SARS-CoV-2 MERS	HFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESL TNCIAPVNGYFIKTNNTRIVDEMSTTGSSFYAPEPITSLNTKYVAPQVTYQNI-STNLPPPLLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESY * :* *:	
SARS-CoV-2 MERS	IDLQELGKYEQYIKWP 1210 IDLKELGNYTYYNKWPWYIWLGFIAGLVALALCVFFILCCTGCGTNCMGKLKCNRCCDRYEEYDLEPHKVHVH 1353 ***:***:* * ***	
Suppler	mentary Figure 3: Amino acid sequence alignment of spike (S) proteins from SA	۹RS-
CoV-2 a	nd MERS-CoV. RBD regions (SARS-CoV-2, residue 319-541 and MERS, residue 367-6	506)
are hig	nlighted in red. The figure was created with ClustalW2 and reformatted in Ad	obe
Illustrat	or CC 2020.	